Abstract
Introduction: Studies are needed to understand the role of CD34 expressing cells with regard to efficient engraftment, especially in the adjuvant treatment of cancer. Materials and Methods: In this study we have used a modified method in our laboratory for routinely counting CD34+ cells. Unlysed whole blood samples were stained with the DNA-selective and cell membrane-permeant Vibrant DyeCycle Violet stain. Results: CD34+ cells exhibit a consistent and differential Vybrant Dye Cycle Violet staining pattern. Based on their different DCV intensity, we classified these subpopulations as CD34+/DCVhigh and CD34+/DCVlow cells. In general, DCVhigh cells are about 12-times brighter than DCVlow cells. Conclusion: DCV staining may be used to discriminate subsets of CD34+ cells similarly to other methods which have previously defined different functional properties that can be related to the characterization, resolution, and purification of primitive hematopoietic stem cells in combination with specific useful markers for multicolor flow cytometric measurements.
Keywords: CD34, flow cytometry, P-glycoprotein, Stem cells, Vybrant DyeCycle Violet.
Current Stem Cell Research & Therapy
Title:Vybrant DyeCycle Violet Stain Discriminates Two Different Subsets of CD34+ Cells
Volume: 11 Issue: 1
Author(s): Cristian Nunez-Espinosa, María D. Garcia-Godoy, Ines Ferreira, Juan G. Rios-Kristjansson, David Rizo-Roca, Laura G. Rico, Gerard Rubi-Sans, Carlos Palacio, Joan R. Torrella, Teresa Pages, Mike D. Ward, Gines Viscor and Jordi Petriz
Affiliation:
Keywords: CD34, flow cytometry, P-glycoprotein, Stem cells, Vybrant DyeCycle Violet.
Abstract: Introduction: Studies are needed to understand the role of CD34 expressing cells with regard to efficient engraftment, especially in the adjuvant treatment of cancer. Materials and Methods: In this study we have used a modified method in our laboratory for routinely counting CD34+ cells. Unlysed whole blood samples were stained with the DNA-selective and cell membrane-permeant Vibrant DyeCycle Violet stain. Results: CD34+ cells exhibit a consistent and differential Vybrant Dye Cycle Violet staining pattern. Based on their different DCV intensity, we classified these subpopulations as CD34+/DCVhigh and CD34+/DCVlow cells. In general, DCVhigh cells are about 12-times brighter than DCVlow cells. Conclusion: DCV staining may be used to discriminate subsets of CD34+ cells similarly to other methods which have previously defined different functional properties that can be related to the characterization, resolution, and purification of primitive hematopoietic stem cells in combination with specific useful markers for multicolor flow cytometric measurements.
Export Options
About this article
Cite this article as:
Nunez-Espinosa Cristian, Garcia-Godoy D. María, Ferreira Ines, Rios-Kristjansson G. Juan, Rizo-Roca David, Rico G. Laura, Rubi-Sans Gerard, Palacio Carlos, Torrella R. Joan, Pages Teresa, Ward D. Mike, Viscor Gines and Petriz Jordi, Vybrant DyeCycle Violet Stain Discriminates Two Different Subsets of CD34+ Cells, Current Stem Cell Research & Therapy 2016; 11 (1) . https://dx.doi.org/10.2174/1574888X10666150528152547
DOI https://dx.doi.org/10.2174/1574888X10666150528152547 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia
Combinatorial Chemistry & High Throughput Screening The Mechanism in Gastric Cancer Chemoprevention by Allicin
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Unlocking the Potential of Stem Cells in Cell Therapy, Drug Delivery and Drug Discovery)
Current Drug Delivery Quinoxalines Potential to Target Pathologies
Current Medicinal Chemistry Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets Advances in Targeted Gene Delivery
Current Drug Delivery Zebrafish As a Genetic Model in Pre-Clinical Drug Testing and Screening
Current Medicinal Chemistry Immunotherapy of Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma
Current Cancer Therapy Reviews Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology Contrast Enhanced Sonography for Diagnosis of (Peri-) Splenic Pathology
Current Medical Imaging Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy
Current Pharmaceutical Design Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine The Role of Tumor Suppressor DLC-1: Far From Clear
Anti-Cancer Agents in Medicinal Chemistry